Press releases | UCB
UCB's Global Corporate Website

This section is intended for media and financial analysts

Search Press releases

12 Dec 2022

Changes in UCB’s Board of Directors

Read More
9 Dec 2022

UCB Announces Positive Phase 3 Studies for Bimekizumab in Hidradenitis Suppurativa

Read More
7 Dec 2022

The Lancet Publishes Results from Two Bimekizumab Phase 3 Studies in Psoriatic Arthritis

Read More
1 Dec 2022

UCB to present data at the American Epilepsy Society 76th Annual Meeting 2022 supporting a decades-long commitment to transforming epilepsy care

Read More
22 Nov 2022

UCB Submits Response to FDA Complete Response Letter for Bimekizumab

Read More
14 Nov 2022

UCB announces U.S. FDA acceptance of new drug application and EMA MAA validation for zilucoplan for the treatment of generalized myasthenia gravis in adult patients

Read More

Stay up-to-date on the latest news and information from UCB